Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Jon Koplik who wrote (1823)	3/16/1999 10:05:00 AM
From: biodoc	Read Replies (1) \| Respond to of 2135

It is negative because an understanding of the mechanism may allow for alternative therapies, ie small molecules, which might be simpler to make and use than either angiostatin or endostatin.

To: Jon Koplik who wrote (1823)	3/16/1999 10:19:00 AM
From: jack velte	Respond to of 2135

Folkman may get a Nobel prize, but will ENMD make money? -jack

To: Jon Koplik who wrote (1823)	3/16/1999 10:30:00 AM
From: tdl4138	Respond to of 2135

It's not Folkman's work that is questioned...its brilliant. What is questioned is the direction that ENMD has taken the ideas.. The news today would indicate that ENMD took a gamble and blew it.

To: Jon Koplik who wrote (1823)	3/16/1999 11:04:00 AM
From: RCMac	Read Replies (1) \| Respond to of 2135

"Progress Reported in Attacking Tumor Blood Supply", in the NYTimes today, reports the same Duke research, and includes the following: "biologists at Duke University have now identified sites on blood vessel cells that are probably the receptors to which angiostatin binds. . . .A colleague, Dr. Salvatore Pizzo, said that now that the binding site was known it might be possible to design a small molecule that would home in on it as accurately as angiostatin does." The article is at nytimes.com -- RCM